by PEPID Newsroom | Jun 4, 2019 | Alerts
The U.S. FDA approved a new indication for Zerbaxa (Ceftolozane and tazobactam) for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABD/VABP) in patients 18 years and older. This approval addresses the threat of...
